Oncology treatment developer Relay Therapeutics is advancing research from several universities and has now filed for a $200m IPO.
Relay Therapeutics, a US-based oncology therapy developer based on research from multiple institutions, filed on Wednesday to raise up to $200m in an initial public offering.
Relay is developing targeted small molecule cancer drugs using discoveries in protein motion and how it relates to the function of proteins that had previously been regarded as undruggable.
Part of the IPO proceeds will fund phase 1 and 1b clinical trials for a drug candidate called RLY-1971 for solid tumours…
